Analyst Justin Walsh of JonesTrading reiterated a Buy rating on Rapport Therapeutics, Inc. (RAPP – Research Report), retaining the price target of $42.00.
Justin Walsh has given his Buy rating due to a combination of factors including the promising development timelines and upcoming data readouts for Rapport Therapeutics, Inc. The company is on track to report topline data from its Phase IIa trial of RAP-219 in refractory focal epilepsy by the third quarter of 2025, which is expected to demonstrate a favorable clinical profile. This upcoming data is anticipated to validate the clinical efficacy of RAP-219, potentially leading to increased interest and momentum for the company.
Additionally, Rapport Therapeutics is preparing to initiate a Phase IIa trial for RAP-219 in bipolar mania and is finalizing plans for a trial in diabetic peripheral neuropathic pain. The involvement of key opinion leaders, such as Dr. Jacqueline French, and the company’s participation in significant industry events further support the positive outlook. These strategic developments and the innovative approach in their trials contribute to the Buy rating, with a price target set at $42.
Walsh covers the Healthcare sector, focusing on stocks such as Achieve Life Sciences, Theratechnologies, and Actinium Pharmaceuticals. According to TipRanks, Walsh has an average return of -3.8% and a 29.49% success rate on recommended stocks.
In another report released on April 30, Stifel Nicolaus also reiterated a Buy rating on the stock with a $35.00 price target.